Vancouver, British Columbia, April 24, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced the enrolment and successful dosing of the first patient in a Phase I clinical study evaluating PRX302 to treat benign prostatic hyperplasia (BPH), commonly called enlarged prostate, a disease that affects one million Canadian men.
